Industry still cares about switching
This article was originally published in OTC Bulletin & The Rose Sheet
Industry was “absolutely interested in switches”, insisted Dirk Ossenberg-Engels, head of Bayer Consumer Health’s Europe South, Central Eastern Europe and Middle East business unit, after the sector’s commitment to prescription-to-OTC reclassification was challenged by Christa Wirthumer-Hoche, chair of the management board of the European Medicines Agency (EMA).
You may also be interested in...
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.